Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 13/20 | 0.58 |
| ▸ | CCL5 | P13501 | 7/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277909 | 0.87 | CCR5 (0.59) | CCR5CCL5 | |
| SCHEMBL3283305 | 0.85 | CCR5 (0.58) | CCR5GRIN2BHCRTR1HCRTR2 | |
| SCHEMBL3290783 | 0.83 | CCR5 (0.67) | CCR5CCL5 | |
| SCHEMBL14626227 | 0.81 | CCR5 (0.68) | CCR5CCL5 | |
| SCHEMBL13326686 | 0.81 | CCR5 (0.68) | CCR5CCL5 | |
| SCHEMBL14626671 | 0.81 | CCR5 (0.60) | CCR5CCL5 | |
| SCHEMBL13326784 | 0.81 | CCR5 (0.60) | CCR5CCL5 | |
| SCHEMBL4694005 | 0.80 | CCR5 (0.59) | CCR5CCL5 | |
| SCHEMBL3282633 | 0.79 | CCR5 (0.55) | CCR5CCL5HCRTR1HCRTR2 | |
| SCHEMBL3282627 | 0.79 | CCR5 (0.56) | CCR5CCL5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | CCR5 1/4885CCL5 7/4885GRIN2B 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.